Engineered Tissue Solutions (ETS)
Engineered Tissue Solutions (ETS) is an innovative company in the medical device industry, dedicated to empowering wound healing with bioactive glass solutions.
ETS, headquartered in Rolla, Missouri, USA, specializes in developing medical products utilizing proprietary borate-based bioactive glass technology. Our flagship product, Mirragen®, represents a breakthrough as the first FDA-cleared bioactive glass-based technology in wound care.
Mirragen® is a borate-based bioactive glass fiber matrix that facilitates quality tissue formation, without the risk of infection that tissue-based products have, all in an easy to use, versatile form factor.
In a wound care market often reliant on tissue-based products with inherent infection risks and storage challenges, Mirragen® offers a distinct advantage. This borate-based bioactive glass fiber matrix supports quality tissue formation and its synthetic composition reduces infection risks associated with tissue-based products, providing safe, consistent results across various wound types, especially for critical limb salvage cases in hospital-based settings, from operating rooms to outpatient wound centers. Stored at room temperature and available in a flexible, versatile form, Mirragen® ensures dependable, efficient care for both clinicians and patients.
*Mirragen Advanced Wound Matrix is intended for use in the management of wounds. Wound types include: partial- and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled and undermined wounds, surgical wounds (such as donor sites and grafts, post-Mohs and post-laser surgeries), podiatric wounds, wound dehiscence, trauma wounds (including abrasions, lacerations, first- and second-degree burns, skin tears), and other draining wounds.
“Three critical barriers still persist today when it comes to healing complex wounds: a lack of wound bed activity to create sufficient quality tissue and angiogenesis, the risk of infection due to potential bioburden in the wound bed, and the need for multiple products on the shelf to fit different wound sizes and depths. Our groundbreaking solution aims to address all three of these challenges in a way that no other skin substitute can.”
AJ Ford, CEO, Engineered Tissue Solutions
Management
